Abstract
Topoisomerase 1 (Top1) and 2 (Top2) are common targets of anti-cancer drugs, which induce specific DNA lesions that are thought to lead to cell death in tumour cells. Camptothecin blocks DNA religation in the Top1–DNA complex and induces Top1-attached nick DNA lesions (Top1–DNA damage). We propose that nucleotide excision repair (NER) factors, excision repair cross complementing 1 protein-xeroderma pigmentosum group F (ERCC1–XPF) endonuclease, and replication protein A (RPA), participate in the repair of Top1-attached nick DNA lesions. ERCC1–XPF exhibits nuclease activity in the presence of RPA on a 3′-phosphotyrosyl bond nick-containing DNA (3′-Tyr-nick DNA) substrate, which mimics a Top1-attached nick DNA lesion. Moreover, repair of the 3′-Tyr-nick DNA occurred in the presence of NER factors, including ERCC1–XPF, RPA, DNA polymerase delta, flap endonuclease 1 (FEN1) and DNA ligase 1 (LIG1). We also illustrate a repair model for DNA lesions induced by Top2 inhibitor etoposide (VP-16), Top2-attached nick DNA (Top2-DNA damage). FEN1 participates in the cleavage of the 5′-phosphotyrosyl bond nick-containing DNA (5′-Tyr-nick DNA) substrates, which mimic Top2-attached nick DNA lesions. Under DNA repair synthesis conditions, FEN1 efficiently repaired the 5′-Tyr-nick DNA substrates in the presence of other base excision repair (BER) factors, LIG1 and DNA polymerase beta (POLB). Taken together, some of the NER and BER machinery might represent an alternative repair pathway for Top1- and Top2-DNA damage.
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Disclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.